This is a real business with real hardware, but it is still a sequence-sensitive premium equity. The main risks are
Neutron validation, the timing and integration of Iridium, continued capital needs, and whether Rocket Lab can turn physical capability into more recurring, higher-trust economics before valuation cools faster than execution improves.